Small Interfering RNA (SiRNA) Therapeutics Market

Global Small Interfering RNA (siRNA) Therapeutics Market is valued at USD 433.2 Million in 2020 and is expected to reach USD 724.3 Million by 2027 with a CAGR of 7.62% over the forecast period. 

Global Small Interfering RNA (siRNA) Therapeutics Market: Global Size, Trends, Competitive, Historical & Forecast Analysis to 2021-2027, Increasing prevalence of cancer and infectious diseases, growing investments or funding for research & development and rising number of clinical trials are some of the major factors driving the growth of the Global Small Interfering RNA (siRNA) Therapeutics Market.

Scope of Global Small Interfering RNA (siRNA) Therapeutics Market

Small interfering RNA (siRNA) is a type of genetic medication that can quiet or take out any over-communicated genes in disease. It's additionally called short interfering RNA. Small interfering RNAs, additionally called as silencing RNA, is a class of double-stranded non-coding RNA particles. These are the most generally utilized nucleic acid-based sequences for interfering expression of particular genes. The siRNAs help to identify extraordinary pathways and to approve focus for different hazardous infections like cancer, AIDS, and so on. These RNAs are broadly used to evaluate the particular commitments of genes to a range of cell phenotypes, including, pancreatic bird signaling, apoptosis, cytokines, and cell separation.

They are utilized to distinguish novel pathways and definitively affect the identification of targets for a few infections like AIDS, malignant growth & hepatitis, and cell measures. The component of the activity of siRNA includes bringing it into cells. siRNA sequences should be intended to coordinate with the short areas of the target gene. Small interfering RNAs are handled by the cell's own enzymes to kill the mRNA of the target gene, so avoiding overexpression of the pathogenic gene. It depends on the natural reaction of cells when they recognize genetic irregularities or diseases. It has a number of advantages over the various sorts of treatments right now accessible, like target specificity, decreased optional impacts, and high specificity.

The Covid-19 pandemic has shown a positive impact on the growth of global small interfering RNA therapeutics market. As COVID-19 cases are increasing day by day, small interfering RNAs are used in treatment. COVID-19 genome is encoded by ribonucleic acid (RNA), making them susceptible to RNA interference, particularly when they are delivered to the lungs. There are few therapies that target viral RNA. During the COVID-19 pandemic, the inborn RNA interference (RNAi) system can be utilized to develop forefront treatments against the infection. This methodology permits particular binding and silencing of therapeutic targets by utilizing short interfering RNA (siRNA) and short hairpin RNA (shRNA) particles.

siRNA Therapeutics Companies: 

Some major key players for global small interfering RNA (siRNA) therapeutics market report cover prominent players like GE, Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, AInylam Pharmaceuticals, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health, and others.

Global Small Interfering RNA and Therapeutics Market Segmentation:

Global small interfering RNA (siRNA) therapeutics market is segmented on the basis of product type, application, and region & country level. Based on product type, the global small interfering RNA (siRNA) therapeutics market is segmented into liposome-based systemic therapy, nanoparticle-based systemic therapy, and others. Based upon application, the market is divided into hospitals, research institutions, academic institutions, pharmaceutical and biotechnology companies, and others.

By Product Type:

• Liposome Based Systemic Therapy
• Nanoparticle-Based Systemic Therapy
• Others

By Application:

• Hospital
• Research Institutions
• Academic Institutions
• Pharmaceutical and Biotechnology Companies
• Others

The regions covered in global small interfering RNA therapeutics market report are North America, Europe, Asia-Pacific, Latin America, and Rest of the World. On the basis of country level, the market of global small interfering RNA therapeutics is sub-divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, India, Japan, South East Asia, Middle East Asia (UAE, Egypt, Saudi Arabia) GCC, Africa, etc.

News: Sirnaomics Received FDA Approval of IND for Phase 1 Clinical Trial of Systemic RNAi Therapeutic STP707 for Solid Tumor Treatment

On July 6^th, 2021; Sirnaomics, Inc. has announced that the organization's IND application for a fundamental siRNA (small interfering RNA) drug applicant, STP707, got the U.S. Food and Drug Administration (FDA) affirmation in patients with advanced strong tumors. Sirnaomics' lead item competitor, STP707, is an anti-cancer siRNA (small interfering RNA) restorative. It takes benefits of a dual-targeted inhibitory property and an exclusive polypeptide nanoparticle (PNP) - improved targeted conveyance to solid tumors and metastatic tumors through the foundational organization. STP707 addresses another significant achievement for the organization's main goal in the invention and advancement of novel siRNA therapeutics for neglected clinical necessities.

Increasing Prevalence of Cancer and Infectious Diseases, Growing Investments or Findings for Research & Development and Rising Number of Clinical Trials are the Key Factors Driving the Market Growth

One of the major factors driving the growth of the global small interfering RNA (siRNA) therapeutics market is the increasing prevalence of cancer and infectious diseases. Cancer analysis and treatment is at present going through a shift with the inclusion of RNAi strategies in personalized medicine and molecular diagnostics. The accessibility of high throughput procedures for the identification of modified cell atoms and metabolites permits the utilization of RNAi techniques in different cancer conclusions and targeting approaches. For diagnostic purposes, small interfering RNAs (siRNA) or micro RNAs (miRNA) can be used. Thus, growing the utilization of RNAi in molecular diagnosis and its suitability as a helpful method is relied upon to drive the development of the RNAi market over the forecast period. For instance; as indicated by the World Health Organization; there are 9.6 million deaths in 2018 and its second-most reason for death is cancer. Out of 6, there is 1 death is because of cancer, worldwide.

In addition, growing investments or findings for research & development are also supplementing the market growth. To develop innovative and more effective treatments for various diseases, a number of governments and private organizations invest in this field. For instance; according to a news published on July 22^nd, 2021; Pharma and Biotech vastly invested in RNA therapeutics to accelerate research and development activities across the globe. Furthermore, rising number of clinical trials are also fostering the global small interfering RNA (siRNA) therapeutics market growth.

However, limited pharmaceutical acceptability of small interfering RNAs and complicated processes may hamper the market growth. In spite of that, increasing technological advancements and growing research and development activities in this field can offer various opportunities for the further growth of the global small interfering RNA (siRNA) therapeutics market.

North America is Expected to Dominate the Global Small Interfering RNA (siRNA) Therapeutics Market

North America is expected to dominate the small interfering RNA (siRNA) therapeutics market within the forecast period due to the increasing number of clinical trials, high investment for research &development activities, and rising healthcare expenditure in this region. For instance; in November 2017, Arcturus Therapeutics converged with Alcobra Ltd. In October 2017, Alnylam and Vir framed essential collusion to progress RNAi therapeutics for irresistible infections. Rising investment and funding for research and development activities are also supplementing the market growth in this region. For example; AstraZeneca's concurrence with Ionis pharmaceuticals is one of the huge deals that are investing intensely into RNA- interference innovation.

Asia Pacific is projected to witness a lucrative growth in the global small interfering RNA (siRNA) therapeutics market attributed to rising awareness about the availability of various therapies available to treat chronic diseases like cancer, cardiovascular diseases and others, increasing healthcare expenditure and presence of favorable reimbursement policies by government in this region.

North America

• U.S.
• Canada

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe

Asia-Pacific

• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Report Analysis	Details
Historical data	2015 - 2020
Forecast Period	2021 - 2027
Market Size in 2020:	USD 433.2 Million
Base year considered	2020
Forecast Period CAGR %:	7.62%
Market Size Expected in 2027:	USD 724.3 Million
Tables, Charts & Figures:	175
Pages	200
siRNA Therapeutics Companies	GE, Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, AInylam Pharmaceuticals, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health, and others.
Segments Covered	By Product Type, By Application
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits for Global small interfering RNA (siRNA) Therapeutics Report–

• Global Small Interfering RNA (siRNA) Therapeutics report covers in-depth historical and forecasts analysis.
• Global Small Interfering RNA (siRNA) Therapeutics research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, siRNA Therapeutics Companies, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.
• Global Small Interfering RNA (siRNA) Therapeutics report helps to identify opportunities in the marketplace.
• Global Small Interfering RNA (siRNA) Therapeutics report covers an extensive analysis of emerging trends and competitive landscape.

Other Related Reports:

• mRNA Vaccines & Therapeutics Market By Type And Forecast to 2027 
• DNA Sequencing Market By Type And Forecast to 2027